Status:
UNKNOWN
Add on Study on Δ9-THC Treatment for Posttraumatic Stress Disorders (PTSD)
Lead Sponsor:
Hadassah Medical Organization
Conditions:
Posttraumatic Stress Disorders
Eligibility:
All Genders
19-60 years
Phase:
PHASE4
Brief Summary
Stress Disorder (PTSD) is a chronic and debilitating anxiety disorder which is widespread in every social level and is very prevalent in outpatient and inpatient settings. A recent open-label study s...
Eligibility Criteria
Inclusion
- Outpatients between the 19-60 years of age with a diagnosis of PTSD.
- Women must not be currently pregnant and must use a reliable method of contraception for the duration of the study.
- Subjects must be on stable medication (4 weeks minimum) for their PTSD (symptomatic despite current treatment), must be able to provide written informed consent, must be able adequately understand and comply with the study's instructions and protocol .
Exclusion
- Those not meeting the inclusion criteria and those not able to give informed consent.
- Women who are currently pregnant or nursing.
- Those at immediate risk of harming self or others; those who have a clinically significant medical illness or other significant psychiatric illness;
- currently abusing alcohol or drugs;
- currently being treated with an investigational medication or medication that is contraindicated with cannabinoids;
- have a known allergy to cannabis-based products.
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2013
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00965809
Start Date
October 1 2009
End Date
April 1 2013
Last Update
October 30 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah Medical Organization
Jerusalem, Israel, 91120